Cell stress proteins: novel immunotherapeutics.

Stuart K Calderwood, Jianlin Gong, Jimmy R Theriault, Salamatu S Mambula, Philip J Gray
{"title":"Cell stress proteins: novel immunotherapeutics.","authors":"Stuart K Calderwood,&nbsp;Jianlin Gong,&nbsp;Jimmy R Theriault,&nbsp;Salamatu S Mambula,&nbsp;Philip J Gray","doi":"10.1002/9780470754030.ch9","DOIUrl":null,"url":null,"abstract":"<p><p>Heat shock proteins (HSPs) play important roles in the immune system as carriers of tumour antigens and inflammatory agents. The HSPs are abundantly expressed stress proteins intrinsic to all cellular life, permitting proteins to carry out essential enzymic, signalling and structural functions within the tightly crowded milieu of the cell. To carry out these tasks, HSPs are equipped with a domain that binds unstructured sequences in polypeptides and a N-terminal ATPase domain that controls the opening and closing of the peptide-binding domain. HSPs can, using these domains, capture antigens processed by partial proteolysis in the cytoplasm of cancer cells. HSP/peptide complexes formed in the cytoplasm can then be secreted to take part in immune surveillance. Extracellular Hsp70 interacts with receptors on antigen presenting cells (APCs) either during episodes of cell death and lysis in vivo or during vaccination. A number of candidate receptors for Hsp70 on APCs have been proposed to take part in the antitumour immune function including the alpha2 macroglobulin receptor CD91, Toll-like receptors, the signalling receptor CD40 and a number of scavenger receptors. Finally, Hsp70 complexes are able to deliver antigens to MHC class I and II molecules on the APC cell surface and lead to the presentation of tumour antigens to T lymphocytes. HSP-antigen complexes have proven effective in the treatment of rodent tumours in preclinical studies and are now undergoing clinical trials for treatment of human cancer.</p>","PeriodicalId":19323,"journal":{"name":"Novartis Foundation Symposium","volume":"291 ","pages":"115-31; discussion 131-40"},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/9780470754030.ch9","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Novartis Foundation Symposium","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/9780470754030.ch9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17

Abstract

Heat shock proteins (HSPs) play important roles in the immune system as carriers of tumour antigens and inflammatory agents. The HSPs are abundantly expressed stress proteins intrinsic to all cellular life, permitting proteins to carry out essential enzymic, signalling and structural functions within the tightly crowded milieu of the cell. To carry out these tasks, HSPs are equipped with a domain that binds unstructured sequences in polypeptides and a N-terminal ATPase domain that controls the opening and closing of the peptide-binding domain. HSPs can, using these domains, capture antigens processed by partial proteolysis in the cytoplasm of cancer cells. HSP/peptide complexes formed in the cytoplasm can then be secreted to take part in immune surveillance. Extracellular Hsp70 interacts with receptors on antigen presenting cells (APCs) either during episodes of cell death and lysis in vivo or during vaccination. A number of candidate receptors for Hsp70 on APCs have been proposed to take part in the antitumour immune function including the alpha2 macroglobulin receptor CD91, Toll-like receptors, the signalling receptor CD40 and a number of scavenger receptors. Finally, Hsp70 complexes are able to deliver antigens to MHC class I and II molecules on the APC cell surface and lead to the presentation of tumour antigens to T lymphocytes. HSP-antigen complexes have proven effective in the treatment of rodent tumours in preclinical studies and are now undergoing clinical trials for treatment of human cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
细胞应激蛋白:新型免疫疗法。
热休克蛋白(HSPs)作为肿瘤抗原和炎症因子的载体在免疫系统中发挥着重要作用。热休克蛋白是所有细胞生命所固有的大量表达的应激蛋白,允许蛋白质在细胞紧密拥挤的环境中执行必要的酶、信号和结构功能。为了完成这些任务,热休克蛋白具有一个结合多肽中非结构化序列的结构域和一个控制肽结合结构域的打开和关闭的n端atp酶结构域。热休克蛋白可以利用这些结构域捕获癌细胞细胞质中经过部分蛋白水解处理的抗原。在细胞质中形成的热休克蛋白/肽复合物可被分泌,参与免疫监视。细胞外Hsp70在体内细胞死亡和裂解期间或接种疫苗期间与抗原提呈细胞(APCs)上的受体相互作用。许多APCs上的Hsp70候选受体已被提出参与抗肿瘤免疫功能,包括α 2巨球蛋白受体CD91、toll样受体、信号受体CD40和一些清道夫受体。最后,Hsp70复合物能够将抗原传递到APC细胞表面的MHC I类和II类分子,并导致肿瘤抗原向T淋巴细胞呈递。在临床前研究中,热休克蛋白抗原复合物已被证明对治疗啮齿动物肿瘤有效,目前正在进行治疗人类癌症的临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
1 months
期刊最新文献
Cardiovascular disease. Normal and neoplastic stem cells. Outer mitochondrial membrane protein degradation by the proteasome. New insights into the role of pendrin (SLC26A4) in inner ear fluid homeostasis. Interaction of prestin (SLC26A5) with monovalent intracellular anions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1